In vitro activity of ceftolozane-tazobactam against Enterobacter cloacae complex clinical isolates with different β-lactam resistance phenotypes - Université de Lorraine Accéder directement au contenu
Article Dans Une Revue Antimicrobial Agents and Chemotherapy Année : 2018

In vitro activity of ceftolozane-tazobactam against Enterobacter cloacae complex clinical isolates with different β-lactam resistance phenotypes

Résumé

The study evaluated the activity of ceftolozane-tazobactam (C/T) against 94 unique clinical isolates of complex (ECC). No difference was observed according to the ECC cluster. The activity greatly varied depending on the β-lactamase-producing profile: 100%, 67%, and 19% of wild-type, extended-spectrum β-lactamase (ESBL)-producing, and AmpC-overproducing strains, respectively, were susceptible to C/T. The use of C/T could be of interest for the treatment of some infections caused by ESBL-producing AmpC-nonoverexpressing ECC isolates.
Fichier principal
Vignette du fichier
Robin - In vitro activity of ceftolozane-tazobactam.pdf (698.28 Ko) Télécharger le fichier
Origine : Fichiers produits par l'(les) auteur(s)
Loading...

Dates et versions

hal-02313665 , version 2 (20-09-2018)
hal-02313665 , version 1 (11-10-2019)

Identifiants

Citer

Frédéric Robin, Michel Auzou, Richard Bonnet, Romain Lebreuilly, Christophe Isnard, et al.. In vitro activity of ceftolozane-tazobactam against Enterobacter cloacae complex clinical isolates with different β-lactam resistance phenotypes. Antimicrobial Agents and Chemotherapy, 2018, 62 (9), pp.e00675-18. ⟨10.1128/AAC.00675-18⟩. ⟨hal-02313665v2⟩
307 Consultations
237 Téléchargements

Altmetric

Partager

Gmail Facebook X LinkedIn More